NICE withdraws backing for 'life-transforming' asthma drug

The UK's drug watchdog is set to revoke its approval of a treatment for severe asthma after a fresh review of the evidence, prompting strong criticism from GPs and charities.

NICE: charities concerned after backing for asthma drug withdrawn
NICE: charities concerned after backing for asthma drug withdrawn

Omalizumab had been approved by NICE to treat severe, persistent allergic asthma in adults in 2007, although it was rejected for use in children.

But now NICE has withdrawn its recommendation in updated draft guidance, saying the drug is 'not as clinically or cost-effective as was first thought'.

Charity Asthma UK called the decision 'surprising and disappointing'.

Severe persistent allergic asthma affects over 14,000 people in the UK. Omalizumab, branded as Xolair and administered by injection, is prescribed by specialists when standard treatments such as high-dose corticosteroids or long-acting beta-2 agonists have failed to control symptoms. It has been shown to cut hospital admissions by 61%.But a new analysis published today in draft form does not recommend omalizumab for use by the NHS. It again rejected its use in children.

Although treatments can still be prescribed without NICE approval, commissioners have often clamped down on this activity in the past.

'Retrograde step'
Leicestershire GP and Primary Care Respiratory Society member Dr Dermot Ryan said the decision was a 'retrograde step'.  'For those people who respond, it has been absolutely life-transforming, stopping them from ending up in hospital and allowing them to go back to work,' he said.

He criticised NICE for focusing more on budgets than patient care. 'I think there's more to medicine than just the sums involved. It's very clear there are a small number of people who benefit from this medication. More expensive treatments with less defined benefits seem to be approved. This decision can only move to undermine NICE's credibility with the health profession.'

Asthma UK chief executive Neil Churchill said: 'There is no doubt that without it, more people with asthma will suffer frequent life-threatening asthma attacks and disabling daily symptoms. We find it hard to understand why NICE wants to change its previous recommendation when there is no major new evidence to suggest that it is any less effective than was previously thought.'

The drug costs around £8,000 per patient per year. Around 2,000 people are thought to be taking omalizumab, while a further 2,000 could benefit from the drug.

The treatment is available in Scotland as it was approved for restricted use by the Scottish Medicines Consortium in June 2011.

Sir Andrew Dillon, NICE chief executive, said the committee behind the guidance 'is aware that severe, persistent allergic asthma can have a detrimental effect on a person’s life' and that omalizumab is an effective treatment. 'But new evidence that has become available since our original appraisal of omalizumab in 2007 indicates that it is not as clinically or cost-effective as was first thought,' he said.

NICE will now run a consultation on the guidance and make a final decision in April.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

BMA mourns 'dark death toll' as UK passes 100,000 COVID-19 deaths

BMA mourns 'dark death toll' as UK passes 100,000 COVID-19 deaths

More than 100,000 people have now died from COVID-19 in the UK, five times the death...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

Viewpoint: End-of-life care in care homes goes well beyond COVID-19

Viewpoint: End-of-life care in care homes goes well beyond COVID-19

Best practice standards for GPs and teams caring for older people in care homes -...

Locum GPs left behind in patchy COVID-19 vaccine rollout

Locum GPs left behind in patchy COVID-19 vaccine rollout

COVID-19 vaccination for locum GPs has trailed behind the rollout to other doctors,...

Four in five over-80s have had first COVID-19 jab despite weekend slump in vaccinations

Four in five over-80s have had first COVID-19 jab despite weekend slump in vaccinations

Almost 80% of people aged over 80 in the UK have have had at least one dose of COVID-19...

Fitness to practise and revalidation to continue despite pandemic, GMC confirms

Fitness to practise and revalidation to continue despite pandemic, GMC confirms

Revalidation and ongoing fitness to practise cases will continue despite huge pressure...